Navigation Links
Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement

MEMPHIS, Tenn., Feb. 23 /PRNewswire-FirstCall/ -- Smith & Nephew, Inc. (NYSE: SNN, LSE: SN) Orthopaedic Reconstruction & Trauma today announced the introduction of VISIONAIRE Patient Matched instrumentation for use in total knee replacement surgery. The VISIONAIRE system is proprietary technology that uses a patient's MRI and x-rays to create custom surgical instrumentation for use with the Smith & Nephew portfolio of high performance knee implants.

By using instruments designed from each patient's anatomical data, surgeons can accommodate the unique shapes and angles of the joint while precisely aligning the implant. The disposable, patient-specific instruments help surgeons eliminate multiple steps and valuable minutes from knee replacement surgery, thus decreasing the risk of infection as well as the amount of time a patient is under anesthesia.

Additionally, the VISIONAIRE system helps hospitals reduce expenses as it eliminates the sterilization costs associated with the traditional, reusable instruments it replaces.

"VISIONAIRE instrumentation is a mutually beneficial technology for patients, surgeons, hospitals and Smith & Nephew," said Joseph DeVivo, president of Smith & Nephew Orthopaedic Reconstruction & Trauma. "The VISIONAIRE system is a core component of our strategy. Patient matched technology is the future of orthopedics and the future of Smith & Nephew, and this launch represents the start of our efforts."

VISIONAIRE technology received 510(k) clearance from the Food and Drug Administration (FDA) in November 2008 and will be launched in targeted US markets throughout 2009. The company is working to expand its use of this proprietary technology across its portfolio of high performance implants for knee and hip replacement and resurfacing.

Smith & Nephew is the first and only major medical device company to design, build and distribute this powerful new technology for patients suffering from advanced osteoarthritis of the knee. Other implant makers rely on systems designed and built by third parties.

About us

Smith & Nephew is a global medical technology business, specializing in Orthopaedic Reconstruction, Orthopaedic Trauma & Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The company has 8,800 employees and operates in 32 countries around the world. Annual Sales in 2007 were nearly $3.4 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward- looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors. All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

SOURCE Smith & Nephew, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Texcel Medical Appoints Barry Smith as President, CEO
2. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
3. GlaxoSmithKline Reports Q4 and Year End Results 2008
4. January 2009 - Rahu Appoints David Greensmith to Non Executive Directo
5. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
6. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
7. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
8. AUDIO from Medialink and GlaxoSmithKline: FDA Approves Boostrix for Adults
9. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
10. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
11. GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):